DekaBank Deutsche Girozentrale Buys 22,440 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

DekaBank Deutsche Girozentrale grew its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 2.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 987,597 shares of the company's stock after purchasing an additional 22,440 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.76% of Henry Schein worth $74,712,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Morgan Stanley raised its holdings in Henry Schein by 143.4% in the 4th quarter. Morgan Stanley now owns 2,337,890 shares of the company's stock worth $186,727,000 after acquiring an additional 1,377,207 shares during the period. Norges Bank bought a new position in Henry Schein in the 4th quarter worth $109,932,000. Lazard Asset Management LLC raised its holdings in Henry Schein by 1,303.3% in the 3rd quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company's stock worth $92,614,000 after acquiring an additional 1,158,451 shares during the period. Boston Partners raised its holdings in Henry Schein by 4,975.9% in the 3rd quarter. Boston Partners now owns 1,080,598 shares of the company's stock worth $80,229,000 after acquiring an additional 1,059,309 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in Henry Schein in the 2nd quarter worth $36,288,000. Institutional investors own 96.62% of the company's stock.

Insider Buying and Selling at Henry Schein

In other news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares of the company's stock, valued at $5,430,462.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares of the company's stock, valued at $5,430,462.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the sale, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. Company insiders own 1.14% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Evercore ISI boosted their price objective on shares of Henry Schein from $79.00 to $83.00 and gave the stock an "in-line" rating in a report on Wednesday, February 28th. Piper Sandler boosted their price objective on shares of Henry Schein from $78.00 to $86.00 and gave the stock an "overweight" rating in a report on Monday, February 26th. SVB Leerink assumed coverage on shares of Henry Schein in a report on Monday, February 26th. They set a "market perform" rating and a $78.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Henry Schein from $82.00 to $88.00 and gave the stock an "overweight" rating in a report on Wednesday, March 6th. Finally, Barrington Research lifted their target price on shares of Henry Schein from $82.00 to $90.00 and gave the company an "outperform" rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Henry Schein has a consensus rating of "Hold" and a consensus target price of $81.09.

Henry Schein Price Performance

NASDAQ:HSIC traded down $0.37 on Friday, reaching $72.52. The stock had a trading volume of 581,611 shares, compared to its average volume of 1,046,018. The company has a market capitalization of $9.32 billion, a P/E ratio of 23.02, a price-to-earnings-growth ratio of 1.81 and a beta of 0.87. Henry Schein, Inc. has a 1-year low of $60.01 and a 1-year high of $85.75. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45. The stock has a fifty day moving average price of $75.14 and a 200-day moving average price of $72.63.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing analysts' consensus estimates of $0.70 by ($0.04). The firm had revenue of $3.02 billion during the quarter, compared to analyst estimates of $3 billion. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. Henry Schein's quarterly revenue was down 10.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.21 earnings per share. Research analysts forecast that Henry Schein, Inc. will post 5.07 EPS for the current year.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.